Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928

Manufacturer: Mirum Pharmaceuticals
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in October 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy

Disease description

89 evidence topics · 28 sources

Definition and etiology5 evidence topics · 5 sources
Epidemiology9 evidence topics · 6 sources
Natural history, survival, and mortality12 evidence topics · 8 sources
Pathophysiology7 evidence topics · 5 sources
Diagnosis10 evidence topics · 11 sources
Clinical presentation - signs and symptoms14 evidence topics · 8 sources
Long-term morbidity7 evidence topics · 6 sources
Burden of Fibrodysplasia ossificans progressiva25 evidence topics · 12 sources